Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database - He, Mengjiao; Yang, Jiale; Yan, Simin; Shu, Qing; Liu, Peng Cheng (Scientific reports, 2025)
Keywords: 692/4023; 692/4023/1670/1613; Adalimumab - adverse effects; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antibodies, Monoclonal - adverse effects; Bayesian analysis; Certolizumab Pegol - adverse effects; Child; Child, Preschool; Databases, Factual; Disproportionality analysis; Etanercept; Etanercept - adverse effects; FAERS database; Female; Humanities and Social Sciences; Humans; Infant; Infliximab; Infliximab - adverse effects; Inhibitors; Lupus; Lupus Erythematosus, Systemic - chemically induced; Lupus Erythematosus, Systemic - epidemiology; Lupus nephritis; Male; Middle Aged; Monoclonal antibodies; multidisciplinary; Neural networks; Pericarditis; Pharmacovigilance; Pleurisy; Science; Science (multidisciplinary); Statistical analysis; Systemic lupus erythematosus; Tumor Necrosis Factor Inhibitors - adverse effects; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Young Adult; Systemic lupus erythematosus; FAERS database; Pharmacovigilance; Disproportionality analysis